This free slidepack showcases the main points from Datamonitor Healthcare's Bladder Cancer Pricing, Reimbursement, and Access report. To view the full contents of the report in addition to the slides, log in to your Datamonitor Healthcare account or contact us for access.

Payers are not overly worried about the cost of bladder cancer, due to the relatively small patient population in comparison to other solid tumors. However, with immunotherapies gaining approvals across multiple indications, payers are concerned about the rising spend on these high-cost treatments across the broader oncology market, and suggest that further access controls may need to be implemented in future.

Outline:

• Market Context
• Methodology
• Global Access Levers
• Evidence and Value
• Access to Recently Approved and Pipeline Products
• Access Trends by Country
  
  • US
  • France
  • Germany
  • Italy
  • Spain
  • UK